Should I buy or sell Sol-Gel Technologies stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" SLGL shares. View SLGL analyst ratings or view top-rated stocks .

What is Sol-Gel Technologies' stock price target for 2024?

2 analysts have issued 12 month target prices for Sol-Gel Technologies' stock. Their SLGL share price targets range from $7.00 to $9.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 833.6% from the stock's current price. View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts .

How have SLGL shares performed in 2024?

Sol-Gel Technologies' stock was trading at $1.1050 at the start of the year. Since then, SLGL shares have decreased by 22.5% and is now trading at $0.8569. View the best growth stocks for 2024 here .

Are investors shorting Sol-Gel Technologies?

Sol-Gel Technologies saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 11,100 shares, a decrease of 17.8% from the March 15th total of 13,500 shares. Based on an average daily volume of 29,900 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short. View Sol-Gel Technologies' Short Interest .

When is Sol-Gel Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our SLGL earnings forecast .

How were Sol-Gel Technologies' earnings last quarter?

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.27 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 61.52% and a negative net margin of 1,331.01%.

What other stocks do shareholders of Sol-Gel Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Flexion Therapeutics (FLXN) , Iovance Biotherapeutics (IOVA) , Marker Therapeutics (MRKR) , Teva Pharmaceutical Industries (TEVA) , Viking Therapeutics (VKTX) , Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP) .

When did Sol-Gel Technologies IPO?

Sol-Gel Technologies (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.

How do I buy shares of Sol-Gel Technologies?

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:SLGL

Sol-Gel Technologies (SLGL) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free SLGL Stock Alerts

$0.86

-0.09 (-9.50%)

(As of 04/17/2024 ET)

Compare

Today's Range: $0.86
▼
$1.00
50-Day Range: $0.82
▼
$1.30
52-Week Range: $0.79
▼
$4.20

Volume: 17,382 shs
Average Volume: 35,005 shs
Market Capitalization: $23.87 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

Get Sol-Gel Technologies alerts:

Sol-Gel Technologies MarketRank™ Stock Analysis

Analyst Rating: Strong Buy
3.50 Rating Score
Upside/Downside: 833.6% Upside
$8.00 Price Target
Short Interest: Healthy
0.12% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.67) to ($0.41) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.63 out of 5 stars

Medical Sector

241st out of 913 stocks

Pharmaceutical Preparations Industry

95th out of 427 stocks

3.8

Analyst's Opinion

Consensus Rating
Sol-Gel Technologies has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Sol-Gel Technologies has received no research coverage in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.12% of the float of Sol-Gel Technologies has been sold short.
Short Interest Ratio / Days to Cover
Sol-Gel Technologies has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sol-Gel Technologies has recently decreased by 17.78%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Sol-Gel Technologies does not currently pay a dividend.
Dividend Growth
Sol-Gel Technologies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SLGL.

3.3

News and Social Media Coverage

News Sentiment
Sol-Gel Technologies has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Sol-Gel Technologies this week, compared to 0 articles on an average week.
MarketBeat Follows
7 people have added Sol-Gel Technologies to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sol-Gel Technologies insiders have not sold or bought any company stock.
Percentage Held by Insiders
66.51% of the stock of Sol-Gel Technologies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 26.18% of the stock of Sol-Gel Technologies is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Sol-Gel Technologies are expected to grow in the coming year, from ($0.67) to ($0.41) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sol-Gel Technologies is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sol-Gel Technologies is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sol-Gel Technologies has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto Swap Profits

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

Secure Your Spot Now

About Sol-Gel Technologies Stock (NASDAQ:SLGL)

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

SLGL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

SLGL Stock News Headlines

April 15, 2024 | americanbankingnews.com

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Short Interest Down 17.8% in March

April 1, 2024 | globenewswire.com

Sol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

March 23, 2024 | investing.com

Sol Gel Technologies Ltd (SLGL)

March 16, 2024 | finance.yahoo.com

SLGL May 2024 2.500 put

March 14, 2024 | benzinga.com

Sol-Gel Technologies: Q4 Earnings Insights

March 14, 2024 | finance.yahoo.com

Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line

March 14, 2024 | finanznachrichten.de

Sol-Gel Technologies Ltd.: Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

April 18, 2024 | Darwin (Ad)

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

March 13, 2024 | globenewswire.com

Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

February 28, 2024 | finance.yahoo.com

Sol-Gel Technologies Ltd. (SLGL) stock forecast and price target

February 22, 2024 | benzinga.com

Sol-Gel Technologies Stock (NASDAQ:SLGL), Quotes and News Summary

December 9, 2023 | markets.businessinsider.com

Optimistic Buy Rating for Sol-Gel Technologies on Revolutionary Topical Treatment SGT-610’s Market Potential

November 30, 2023 | finanznachrichten.de

Sol-Gel Technologies Ltd.: Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

November 30, 2023 | finance.yahoo.com

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

November 28, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610

November 20, 2023 | finance.yahoo.com

Is Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Trading At A 24% Discount?

November 9, 2023 | msn.com

Sol-Gel Technologies GAAP EPS of -$0.21 beats by $0.02, revenue of $0.21M misses by $0.48M

November 9, 2023 | finance.yahoo.com

Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 31, 2023 | finance.yahoo.com

Zacks Industry Outlook Highlights Dr. Reddy's Laboratories, Amphastar Pharmaceuticals and Sol-Gel Technologies

October 10, 2023 | finance.yahoo.com

Is Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Invest In Growth?

August 30, 2023 | finance.yahoo.com

Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | msn.com

HC Wainwright & Co. Maintains Sol-Gel Technologies (SLGL) Buy Recommendation

August 11, 2023 | markets.businessinsider.com

Expert Ratings for Sol-Gel Technologies

August 10, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates

August 10, 2023 | finance.yahoo.com

Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update

July 21, 2023 | finance.yahoo.com

Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Top Key Executive Moshe Arkin is the most upbeat insider, and their holdings increased by 15% last week

See More Headlines

Receive SLGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sol-Gel Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/13/2024
Today: 4/17/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:SLGL
CUSIP: N/A
CIK: 1684693
Web: www.sol-gel.com
Phone: (728) 931-3433
Fax: 972-153-523044444
Employees: 36
Year Founded: 1997

Price Target and Rating

Average Stock Price Target: $8.00
High Stock Price Target: $9.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +833.6%
Consensus Rating: Strong Buy
Rating Score (0-4): 3.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,240,000.00
Net Margins: -1,331.01%
Pretax Margin: -1,752.77%
Return on Equity: -61.52%
Return on Assets: -53.75%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.10
Quick Ratio: 9.10

Sales & Book Value

Annual Sales: $1.55 million
Price / Sales: 15.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 0.51

Miscellaneous

Outstanding Shares: 27,860,000
Free Float: 9,330,000
Market Cap: $23.87 million
Optionable: Optionable
Beta: 1.33

Social Links

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Dr. Alon Seri-Levy (Age 63)
Co-Founder, CEO & Director
Comp: $411k
Mr. Gilad Mamlok (Age 56)
Chief Financial Officer
Comp: $367k
Dr. Itzik Yosef (Age 48)
Chief Operating Officer
Comp: $236k
Mr. Moshe Arkin (Age 71)
Executive Chairman of the Board
Prof. David Avnir
Co-Founder
Ms. Tamar Fishman Jutkowitz (Age 48)
VP & General Counsel
Dr. Karine Neimann (Age 53)
VP of Projects & Planning and Chief Chemist

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SLGL Stock Analysis - Frequently Asked Questions

Should I buy or sell Sol-Gel Technologies stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" SLGL shares.
View SLGL analyst ratings or view top-rated stocks.
What is Sol-Gel Technologies' stock price target for 2024?: 2 analysts have issued 12 month target prices for Sol-Gel Technologies' stock. Their SLGL share price targets range from $7.00 to $9.00. On average, they expect the company's share price to reach $8.00 in the next year. This suggests a possible upside of 833.6% from the stock's current price.
View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts.
How have SLGL shares performed in 2024?: Sol-Gel Technologies' stock was trading at $1.1050 at the start of the year. Since then, SLGL shares have decreased by 22.5% and is now trading at $0.8569.
View the best growth stocks for 2024 here.
Are investors shorting Sol-Gel Technologies?: Sol-Gel Technologies saw a decrease in short interest during the month of March. As of March 31st, there was short interest totaling 11,100 shares, a decrease of 17.8% from the March 15th total of 13,500 shares. Based on an average daily volume of 29,900 shares, the short-interest ratio is presently 0.4 days. Approximately 0.1% of the shares of the company are sold short.
View Sol-Gel Technologies' Short Interest.
When is Sol-Gel Technologies' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our SLGL earnings forecast.

How were Sol-Gel Technologies' earnings last quarter?: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The firm had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.27 million. Sol-Gel Technologies had a negative trailing twelve-month return on equity of 61.52% and a negative net margin of 1,331.01%.
What other stocks do shareholders of Sol-Gel Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).
When did Sol-Gel Technologies IPO?: Sol-Gel Technologies (SLGL) raised $60 million in an initial public offering on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. Jefferies and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities and Raymond James were co-managers.
How do I buy shares of Sol-Gel Technologies?: Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLGL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial